Mouse Monoclonal ApoE antibody [1H4] (STJ97839)


Reactivity: Human
Applications: WB, IHC, FC, ELISA
Conjugation: Unconjugated
Supplier: St John’s Laboratory Ltd.

-$50 as credit for submitting review for primary antibody
Shipping notice:
Product will be delivered in 6 to 8 Business Days

Mouse Monoclonal ApoE antibody [1H4] (STJ97839)

Supplier: St John’s Laboratory Ltd.

Recommended applications: WB, IHC, FC, ELISA

Recommended dilution: WB 1:500-1:2000; IHC 1:200-1:1000; FC 1:200-1:400; ELISA 1:10000

Recommended protocols: check protocols

Image descriptions:

Click or hover above images to see image description for ApoE Monoclonal Antibody.

Alternative names:

Check alternative names for the antibody


APOE antibody,|AD2 antibody|Apo-E antibody|APOE antibody|APOE_HUMAN antibody|APOEA antibody|Apolipoprotein E antibody|Apolipoprotein E3 antibody|ApolipoproteinE antibody|Apoprotein antibody|LDLCQ5 antibody|LPG antibody|Anti-Apolipoprotein E antibody [D6E10] (ab1906)
SCBT cat No: sc-393773|sc-6383|sc-393302|sc-390925|sc-31823|



ApoE Monoclonal Antibody

Catalogue No.





ApoE Monoclonal Antibody detects endogenous levels of ApoE protein.


Purified recombinant fragment of human ApoE expressed in E Coli





Recommended dilution

WB 1:500-1:2000; IHC 1:200-1:1000; FC 1:200-1:400; ELISA 1:10000








ApoE Antibody was tube-contained. Ascitic fluid containing 0.03% sodium azide.


1 mg/ml


ApoE Antibody was purified using affinity purification.


-20 Celsius degree. Avoid repeated freeze/thaw cycles.

Alternative antibody names

Apolipoprotein E antibody, Apo-E antibody

Database links

Human UniProt/Swiss-Prot:P02649;Mouse UniPort/Swiss-Prot: P08226;Rat UniProt/Swiss-Port: P02650;Human Entrez Gene: 348;Mouse Entrez Gene: 11816;Rat Entrez Gene: Rn.32351

Protein names

Apolipoprotein E , Apo-E

Protein function

Mediates the binding, internalization, and catabolism of lipoprotein particles. It can serve as a ligand for the LDL (apo B/E) receptor and for the specific apo-E receptor (chylomicron remnant) of hepatic tissues.

Protein tissue specificity

Occurs in all lipoprotein fractions in plasma. It constitutes 10-20% of very low density lipoproteins (VLDL) and 1-2% of high density lipoproteins (HDL). APOE is produced in most organs. Significant quantities are produced in liver, brain, spleen, lung, adrenal, ovary, kidney and muscle.

Involvement in disease

Hyperlipoproteinemia 3 (HLPP3) [MIM:107741]: A disorder characterized by the accumulation of intermediate-density lipoprotein particles (IDL or broad-beta-lipoprotein) rich in cholesterol. Clinical features include xanthomas, yellowish lipid deposits in the palmar crease, or less specific on tendons and on elbows. The disorder rarely manifests before the third decade in men. In women, it is usually expressed only after the menopause. . Note: The disease is caused by mutations affecting the gene represented in this entry. The vast majority of the patients are homozygous for APOE*2 alleles. More severe cases of HLPP3 have also been observed in individuals heterozygous for rare APOE variants. The influence of APOE on lipid levels is often suggested to have major implications for the risk of coronary artery disease (CAD). Individuals carrying the common APOE*4 variant are at higher risk of CAD.; Alzheimer disease 2 (AD2) [MIM:104310]: A late-onset neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituent of these plaques is the neurotoxic amyloid-beta-APP 40-42 peptide (s), derived proteolytically from the transmembrane precursor protein APP by sequential secretase processing. The cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products such as C31 derived from APP, are also implicated in neuronal death. Note: Disease susceptibility is associated with variations affecting the gene represented in this entry. The APOE*4 allele is genetically associated with the common late onset familial and sporadic forms of Alzheimer disease. Risk for AD increased from 20% to 90% and mean age at onset decreased from 84 to 68 years with increasing number of APOE*4 alleles in 42 families with late onset AD. Thus APOE*4 gene dose is a major risk factor for late onset AD and, in these families, homozygosity for APOE*4 was virtually sufficient to cause AD by age 80. The mechanism by which APOE*4 participates in pathogenesis is not known.; Sea-blue histiocyte disease (SBHD) [MIM:269600]: Characterized by splenomegaly, mild thrombocytopenia and, in the bone marrow, numerous histiocytes containing cytoplasmic granules which stain bright blue with the usual hematologic stains. The syndrome is the consequence of an inherited metabolic defect analogous to Gaucher disease and other sphingolipidoses. . Note: The disease is caused by mutations affecting the gene represented in this entry.; Lipoprotein glomerulopathy (LPG) [MIM:611771]: Uncommon kidney disease characterized by proteinuria, progressive kidney failure, and distinctive lipoprotein thrombi in glomerular capillaries. . Note: The disease is caused by mutations affecting the gene represented in this entry.; Familial hypercholesterolemia (FH) [MIM:143890]: Common autosomal semi-dominant disease that affects about 1 in 500 individuals. The receptor defect impairs the catabolism of LDL, and the resultant elevation in plasma LDL-cholesterol promotes deposition of cholesterol in the skin (xanthelasma), tendons (xanthomas), and coronary arteries (atherosclerosis). . Note: The disease may be caused by mutations affecting the gene represented in this entry.

Protein sequence and domain

Belongs to the apolipoprotein A1/A4/E family.

Protein post-translational modifications

Synthesized with the sialic acid attached by O-glycosidic linkage and is subsequently desialylated in plasma. O-glycosylated with core 1 or possibly core 8 glycans. Thr-307 and Ser-314 are minor glycosylation sites compared to Ser-308. / Glycated in plasma VLDL of normal subjects, and of hyperglycemic diabetic patients at a higher level (2-3 fold). / Phosphorylated by FAM20C in the extracellular medium.

Protein cellular localization


Research area

All research areas>Transport and Trafficking>Apolipoprotein
(View all antibody categories related to Transport and Trafficking)


AntibodyPlus can customize ApoE Antibody according to your requirement, including bulk product size,etc. Please contact AntibodyPlus provide antibody trial sample for your own antibody validation and collects antibody reviews.


St John’s Laboratory Ltd.

Product type

Primary antibody


There are no reviews yet.

Only logged in customers who have purchased this product may leave a review

There are no reviews for this product yet.
By submitting a review, get following benefits:

1. Receive $50 ABcoins as credit for each review.
2. First trial sample order will be fully refunded as credit.
3. Have a chance to win a $50 amazon gift card!

view database submit reviews

There is no extra validation for this product yet.
Check other extra validated antibodies below:

Welcome to AntibodyPlus!